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The MELD score has shown that, besides markers of liver func-
tion, serum creatinine has a strong prognostic value in cirrhosis.
However, even though creatinine has a good prognostic value, it
is an inaccurate marker of renal function in cirrhosis. Creatinine
and creatinine-based equations tend to overestimate glomerular
ﬁltration rate (GFR), and creatinine clearance from timed urine
collection also overestimates GFR. Hence, clearance of exogenous
markers such as iohexol remains the only reliable method for
assessing precisely GFR in cirrhosis. Whereas these investigations
are limited by their costs and complexity, and they can hardly be
repeated at short intervals, serum cystatin C could be an alterna-
tive, although it needs further validation. Accurate markers and/
or speciﬁc equations are therefore still needed to assess GFR in
cirrhotic patients. Pre-renal failure and hepatorenal syndrome
(HRS) are the main causes of acute renal failure in cirrhosis. Both
result from decreased renal blood ﬂow and both can result in
acute tubular necrosis. HRS is not always fully reversible with
liver transplantation possibly due to underlying chronic kidney
damage. A number of cirrhotic patients with acute renal failure
may also have chronic kidney damage (‘‘acute-on-chronic renal
failure”); furthermore, cirrhotic patients frequently have co-mor-
bidities such as diabetes that may result in chronic impairment in
renal function. Since conventional urinary markers are biased in
cirrhosis, a biopsy is the only way to document and quantify renal
lesions; moreover, transvenous route should be preferred to per-
cutaneous route. In candidates for transplantation, attention
should therefore be focused on vascular lesions which may repre-
sent a risk factor for nephrotoxicities induced by calcineurin-
inhibitors.
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combined liver and kidney transplantation.The determinant impact of serum creatinine on the prognosisFor more than 30 years, the Child–Pugh score has been the
main prognostic tool for patients with cirrhosis [1]. The
Child–Pugh score was based on 5 variables (i.e., ascites, enceph-
alopathy, serum bilirubin, serum albumin and prothrombin
time) which had been empirically selected because they were
felt to have a determinant impact on the outcome. This score
proved to be a robust prognostic tool in a number of situations
[2]. However, it had some limitations, including the subjective
interpretation of ascites and encephalopathy. In the early
2000s, the model for end-stage liver disease (MELD) score
emerged as a simple, more objective, alternative to Child–Pugh
score [3–5]. The 3 variables entered in the MELD score have
been selected on the basis of statistical analysis, not empiri-
cally. The weight associated to each of the variables also derives
from statistical analysis. Interestingly, besides serum bilirubin
and international normalized ratio (INR) which are basic mark-
ers of liver function, the third component of the MELD score,
serum creatinine, is essentially a marker of renal function. This
ﬁnding highlights the prognostic signiﬁcance of the interactions
between liver function and renal function in cirrhosis. The value
of creatinine weighs heavily on the MELD score [5]. As an
example, an increase in serum creatinine from 1 to 1.5 mg/dl
(88 to 132 lmol/L) in a patient with a bilirubin of 2.9 mg/dl
(50 lmol/L) and an INR of 1 results in a 40% increase in the
MELD score.
The MELD score has been widely validated in different popu-
lations of cirrhotic patients [6]. However, it has been suggested
recently that creatinine weighs too heavily on the MELD score
[7]. In addition, it has been pointed out that patients with serum
creatinine below 1 mg/dl are bounded to 1 mg/dl in order to
avoid negative values after logarithmic transformation. A rela-
tively large number of cirrhotic patients have baseline serum cre-
atinine below 1 mg/dl and some of them have signiﬁcant
impairment in renal function. The assumption that mortality is
constant for creatinine less than 1 mg/dl is likely to be false. As
a result, a modiﬁed MELD score including loge (1 + creatinine
[mg/dl]) without bounding and a lower weight for creatinine
compared to the current MELD score has been proposed [7]. This
modiﬁed score seems to be slightly superior the current MELD
score. However, even after these adjustments, creatinine still
has a determinant prognostic value.10 vol. 52 j 605–613
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From serum creatinine to renal function in cirrhotic patients:
many sources of discordance
Creatine is the simplest and the most widely used marker of renal
function in the general population. However, it is a paradox that
even if creatinine is a powerful prognostic marker in cirrhosis, it
is an inaccurate marker of renal function in most cirrhotic
patients. Indeed, in these patients, there are many biases and pit-
falls in the interpretation of creatinine as well as creatinine-based
estimates of renal function.
Interpretation of serum creatinine
Creatine is synthesized in the liver before being stored in muscles
where it is phosphorylated as creatinine. The production of creat-
inine varies little from day to day. This small compound is freely
ﬁltered by the kidney but it can also be secreted by the proximal
tubule. The ratio between creatinine secreted by the tubule to the
amount of creatinine ﬁltered by the glomerulus increases as glo-
merular ﬁltration rate (GFR) decreases. In addition to muscle
mass and protein intake, creatinine is inﬂuenced by age, gender
and ethnicity.
Several reasons make that in cirrhotic patients, serum creati-
nine may overestimate renal function. Impaired liver function
results in decreased creatinine production. Protein-calorie mal-
nutrition and muscle wasting which are common during cirrhosis
[8,9] also contribute to decreased creatinine production. On aver-
age, baseline serum creatinine is lower in cirrhotic patients com-
pared to the general population [10,11]. Baseline serum
creatinine within the normal range does not exclude a signiﬁcant
impairment in renal function [12–15]. Patients may present a
twofold increase in baseline creatinine with levels remaining
below 1 mg/dl (88 lmol/L), apparently within the normal range.
Another bias comes from ﬂuctuations of serum creatinine, espe-
cially in those with refractory ascites and/or those receiving
diuretics. Wide variations may be observed, depending on large
volume paracentesis and volume expansion. In such situations,
the issue of which serum creatinine value is best correlated to
the outcome is difﬁcult to address.
Signiﬁcant inter-laboratory variations may be observed in
the dosage of creatinine, mainly due to an interaction with bili-
rubin [16,17]. Routine creatinine dosage is based on spectropho-
tometry. In patients with jaundice, bilirubin as a chromogen
interferes with creatinine dosage, resulting in falsely low creat-
inine values. The higher is serum bilirubin, either conjugated or
unconjugated, the higher is the interference. It has been shown
that inter-laboratory variations may impact on MELD score [18].
For example, when four different methods of creatinine dosage
are applied in patients with serum bilirubin between 200 and
400 lmol/L, a difference in MELD scoreP2 points may be
observed in about 60% [18]. Several techniques such as depro-
teinization, the use of bilirubin oxidase or kinetic alkaline pic-
rate methods may help overcome this interference [19,20].
However, the dosage of serum creatinine has not been
standardized.
On an individual basis, serum creatinine should be interpreted
with caution in cirrhotic patients due to frequent overestimation
of renal function. Overestimation is especially high in patients
with advanced liver disease, high bilirubin and refractory ascites.
Therefore, creatinine alone is insufﬁcient for identifying either
acute or chronic renal disease in these patients.606 Journal of Hepatology 201Creatinine clearance from timed urine collections: friend or foe?
In theory, creatinine clearance from timed urine collections
might be a reliable method for assessing renal function. However,
several studies have shown that, in cirrhotic patients, creatinine
clearance, when compared to inulin clearance as the reference
standard, overestimates true GFR by a mean of about 13 ml/
min/1.73 m3 [15,21–23]. Overestimation is highest in patients
with low GFR [23].
The reasons for the discordance between creatinine clearance
and true GFR could be related, at least in part, to the increased
proportion of creatinine secreted by the tubule compared to cre-
atinine ﬁltered by the glomerulus during cirrhosis, especially in
those with low GFR [22]. From a practical view point, non speciﬁc
factors including incomplete urine collection and errors in the
timing of collection may play a more difﬁcult to identify role in
the inaccuracy of creatinine clearance.
Creatinine clearance based on timed urine collections, even if
well conducted, is not the guarantee of an accurate assessment of
renal function in cirrhotic patients. Overestimation may lead to
inappropriate classiﬁcation and/or therapeutic adjustments in
about 50% patients [23]. There is no evidence that creatinine
clearance is preferable to serum creatinine.
Creatinine-based equations: deﬁnitely foe
The creatinine-based Cockcroft and MDRD equations are widely
used in the general population to estimate GFR [10,11]. MDRD
is considered the gold standard in nephrology [24]. However, as
these equations are based on serum creatinine, it is not surprising
that they are also inaccurate in cirrhotic patients. Several studies
have shown that both Cockcroft and MDRD tend to overestimate
true GFR [12,14,22,25]. The largest series has shown that only
66% of estimates were within 30% of the measured GFR [26]. In
cirrhotic patients, MDRD which does not take into account body
weight seems to be less inaccurate than Cockcroft [26]. Indeed,
body weight may be markedly biased in patients with oedema
and/or ascites. However, the accuracy of MDRD, even if slightly
superior to that of Cockcroft, remains limited [12].
The inaccuracy of Cockcroft and MDRD in cirrhotic patients
may be related to several factors. As discussed above, creatinine
is an inaccurate marker of renal function in this population. In
particular, normal serum creatinine does not exclude a marked
decrease in GFR. Secondly, Cockcroft and MDRD equations
include serum creatinine adjusted for several variables which
were shown to have a signiﬁcant impact on GFR in the general
population (i.e., age, body weight and gender for Cockcroft; age,
gender and ethnicity for simpliﬁed MDRD). The factors associ-
ated with each of these variables are not necessarily well suited
for cirrhotic patients. Different adjustments could be needed.
Finally, Cockcroft and MDRD are not adjusted for some vari-
ables which are likely to have a determinant impact on the esti-
mation of GFR in cirrhotic patients. For example, body weight is
difﬁcult to interpret without taking into account ascites and
oedema.
Recently, a new creatinine-based equation termed CKD-EPI
(for Chronic Kidney Disease Epidemiology Collaboration),
adjusted for gender and ethnicity has been proposed as a more
accurate formula compared to Cockcroft and MDRD [27]. This for-
mula has not been tested in cirrhotic patients yet. However, as it
is also based on serum creatinine, it can be anticipated that CKD-0 vol. 52 j 605–613
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EPI is not markedly superior to other creatinine-based equations
in cirrhosis.
Creatinine-based equations should not be recommended to
estimate renal function in cirrhotic patients. Indeed, these formu-
las may give falsely reassuring values since they tend to overes-
timate GFR. More data are needed to create and validate more
speciﬁc equations with an acceptable accuracy in cirrhosis. To
date, no such equations have been proposed.Alternatives to creatinine and creatinine-based equation for
the assessment of renal function
Clearance of exogenous markers
Direct measurement of GFR using exogenous markers remains
the reference to assess renal function in cirrhotic patients. Direct
measurement of GFR is mandatory to precisely assess renal func-
tion and adequately classify patients into the different categories
of impaired renal function (Table 1) [28].
Inulin clearance has been considered the ‘‘gold standard”. Inu-
lin is freely ﬁltered by the glomerulus and not secreted, reab-
sorbed, synthesized or metabolized by the kidney.
Consequently, for a stable concentration of inulin in the plasma,
the amount of ﬁltered inulin by the glomerulus is equal to the
amount excreted in the urine [29]. However, this technique
requires a continuous intravenous infusion and timed urine col-
lections over a period of several hours. This technique is time
consuming, costly and potentially invasive if bladder catheteriza-
tion has to be done for urine collection. Other techniques using
markers such as synthetic inulin-like polyfructosans, radiola-
beled compounds (51Cr-EDTA, 99mTc-DPTA and 125I-iothalamate)
or non-radioactive agents (iohexol or iothalamate) have been
proposed [24,30]. The main advantage of these markers is a sin-
gle-injection with measurement of GFR based on the total area
under the curve of the plasma concentration of the marker. Time
collection of urine samples is not needed. The use of radiolabeled
compounds is limited by exposure to radiation and costs. Con-
trast agents seem to be safer even though rare allergic events
have been reported. None of these alternative techniques have
been speciﬁcally validated in cirrhosis. However, since markers
are exogenous and only eliminated by the kidney, it can be
assumed that their accuracy is similar to that of inulin clearance.
Measurements using iohexol or iothalamate can be recom-
mended. However, these techniques which are technically
demanding and costly can hardly be repeated at close intervals.
Cystatin C and other markers
Recently, it has been shown that serum cystatin C, another
endogenous marker, could represent an interesting alternativeTable 1. Proposed deﬁnitions for staging chronic kidney diseases [28].
Stage Description GFR (ml/min/1.73 m2)
1 Kidney damage* with normal or increased GFR P90
2 Kidney damage with mild decreased GFR 60–89
3 Moderate decreased GFR 30–59
4 Severe decreased GFR 15–29
5 Kidney failure <15 or dialysis
* Kidney damage is deﬁned as pathologic abnormalities or markers of damage
including abnormalities in blood or urine tests or imaging studies.
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protein produced at a constant rate by all nucleated cells and
eliminated almost exclusively by glomerular ﬁltration [31].
After ﬁltration, cystatin C is reabsorbed and catabolized by
the tubular epithelial cells. Consequently, urinary clearance
cannot be measured [24,32]. In contrast to creatinine, serum
cystatin C is independent of gender, age and muscle mass.
The dosage is not inﬂuenced by serum bilirubin, inﬂammation
or malignancy [33,34]. A recent meta-analysis has shown that,
in non-cirrhotic patients, cystatin C is better correlated with
GFR than creatinine [35]. Interestingly, it has been shown that
the sensitivity of cystatin C for the diagnosis of impaired renal
function, with a cut-off value of 1.25 mg/dl, is similar in cir-
rhotic patients and in non-cirrhotic patients [21]. Several
small studies have suggested that, after kidney or liver trans-
plantation, serum cystatin C could be useful to monitor renal
function [36–39]. Finally, several equations using serum cysta-
tin C have been proposed to estimate GFR [40–42]. Although
serum cystatin C is easy to obtain routinely, it has several
limitations. Firstly, the cost of the assay is signiﬁcantly higher
compared to serum creatinine. Secondly, the assays need fur-
ther standardization [32]. Thirdly, serum cystatin C is inﬂu-
enced by infection and by some drugs such as
corticosteroids, angiotensin-converting enzyme inhibitors or
calcineurin inhibitors (CNI) [43,44]. It has been suggested that
cystatin C could be a marker of progression of liver ﬁbrosis
[45,46]. This could represent a potential bias for the assess-
ment of renal function in cirrhotic patients. However, there
is no evidence that the increase in cystatin C in patients with
ﬁbrosis is not correlated to changes in renal function [46].
Apart from cystatin C, other biomarkers, such as b2 micro-
globulin or b–trace protein have been proposed. They do not
seem to be accurate enough for estimating renal function [34].Renal Doppler ultrasonography
Hepatorenal syndrome (HRS) is characterized by renal vasocon-
striction. Renal vasoconstriction has been documented in several
series of cirrhotic patients by Doppler ultrasound (US) analysis of
renal arteries, showing increased resistive index (RI) [47–49]. RI
is determined from the spectral waveforms and corresponds to
the following formula: (peak systolic frequency shift – lowest
diastolic frequency shift)/peak systolic frequency shift. On aver-
age, renal RI is higher in cirrhotic patients compared to healthy
individuals and high RI (over 0.7) can be observed in cirrhotic
patients with serum creatinine within the normal range [47]. In
patients without refractory ascites, RI decreases from the hilum
towards the outer parenchyma, suggesting that the ﬂow to the
cortex is relatively preserved [47]. In contrast, in patients with
refractory ascites, RI is also increased in the cortical vessels sug-
gesting cortical vasoconstriction. Paracentesis and albumin infu-
sion are followed by a signiﬁcant decrease in renal RI [48]. Liver
transplantation is also followed by a decrease in RI [50].
In patients with normal serum creatinine, increased RI seems
to be correlated with a higher risk of subsequent deterioration in
renal function [50]. Therefore, Doppler ultrasound may be an
early marker of renal dysfunction. In candidates for transplanta-
tion, high renal RI is associated with a greater risk of renal dys-
function and dialysis post-transplantation [49]. However, in
cirrhotic patients with impaired renal function, whether high RI
predicts complete recovery is unclear.0 vol. 52 j 605–613 607
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Overall, Doppler US may be useful for identifying patients at
high risk for developing impaired renal function at an early stage.
It may be useful for clarifying the mechanisms involved in renal
insufﬁciency. It may help clarify the role of therapeutic interven-
tion on renal hemodynamics. However, RI is not correlated to GFR
[51]. In addition, there is no evidence that Doppler US helps dif-
ferentiate cirrhotic patients with impaired renal function only
related to vasoconstriction from patients who have both vasocon-
striction and intrinsic kidney damage.Facing the spectrum of causes of impaired renal function in
cirrhosis
Once impaired renal function has been documented, an impor-
tant step is to determine its causes and mechanisms. It may be
a difﬁcult issue to address given that, in the context of cirrhosis,
impaired renal function may result from several cofactors. In
addition, patients with chronic renal damage and baseline
impairment in renal function may present with superimposed
acute renal injury (‘‘acute-on-chronic renal failure”).
Acute renal failure
The two main causes of acute renal failure in cirrhosis are func-
tional (pre-renal) renal failure and HRS type I [52]. The adminis-
tration of nephrotoxic agents (aminoglycosides and non steroidal
anti-inﬂammatory drugs, among others) and aggressive diuretic
therapy also represent possible causes of acute renal failure or
contributing factors (Table 2) [52–54].
Pre-renal failure can be precipitated by hypovolemia (follow-
ing variceal bleeding for instance) and sepsis [55–57]. Although
pre-renal failure and acute tubular necrosis can occur at any
stage of cirrhosis, HRS essentially occurs in patients with
advanced liver insufﬁciency and/or refractory ascites [58]. Basi-
cally, pre-renal failure and HRS result from the same mechanism,
namely, a marked decrease in renal blood ﬂow. During HRS, the
decrease in renal blood ﬂow is secondary to renal vasoconstric-
tion. If reduced renal blood ﬂow persists, both pre-renal failure
and HRS may eventually lead to acute tubular necrosis. However,Table 2. Main causes of acute and chronic kidney diseases in patients with
cirrhosis.*
Acute kidney diseases
Hepatorenal syndrome (type I)
Pre-renal (functional) failure
Acute tubular necrosis
Following hepatorenal syndrome
Following pre-renal failure
Drug-induced (amlinoglycosides, non steroidal anti-inﬂammatory drugs)
Osmotic tubulopathy (contrast agents, hydroxyethyl starch)
Chronic kidney diseases
Diabetic glomerulosclerosis
Ischemic nephropathy
Alcohol-related IgA nephropathy
HCV-related membranoproliferative glomerulonephritis
HBV-related membranous ne phropathy
Non-diabetic glomerulosclerosis
Hepatorenal syndrome (type II)
* This list is not exhaustive.
 Occasionally, type 2 hepatorenal syndrome may progress to end stage renal
disease in less than 3 months.
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renal vasoconstriction has not been clearly documented on a
pathological basis. When patients with HRS develop acute tubu-
lar necrosis, the degree of renal vasoconstriction tends to worsen
due to intense activation of the tubuloglomerular feedback and
reﬂective afferent arteriolar vasoconstriction [59]. Eventually,
prolonged renal ischemia leads to glomerular and interstitial
ﬁbrosis with irreversible consequences [60].
A ﬁrst set of criteria has been proposed in 1996 for the diag-
nosis of HRS [61]. These criteria were complex and restrictive.
In patients with advanced cirrhosis the occurrence of ‘‘func-
tional-like” acute liver failure is frequently triggered by sepsis
or some degree of hypovolemia. Therefore, it was unlikely that
patients with HRS could meet all the criteria. The diagnostic cri-
teria have been revised recently in order to be less restrictive and
more ﬂexible in clinical practice (Table 3) [62]. However, it can be
objected that the revised criteria are not speciﬁc enough and that
the frontier between functional renal failure and HRS in patients
with end-stage cirrhosis becomes artiﬁcial. In a context of end-
stage cirrhosis associated with complications including acute
renal failure, the identiﬁcation of HRS as a speciﬁc disease entity
may still be difﬁcult.
Chronic kidney diseases
Type 2 HRS is characterized by a steady or slowly progressive
course compared to type 1 HRS which progresses rapidly [63].
It has been deﬁned empirically as a moderate increase in serum
creatinine ranging from 1.25 mg/dl and 2.5 mg/dl (110–
220 lmol/L) with a less progressive course than does type 1
HRS [61]. Type 2 HRS is usually associated with refractory ascites
and, even if liver function is relatively preserved, the prognosis is
poor [64,65]. Type 2 HRS is most often considered a cause of
chronic kidney disease in patients with cirrhosis. However, this
classiﬁcation may be misleading as some patients with type 2
HRS can progress to end-stage renal disease in less than
3 months. Renal vasoconstriction and decreased renal blood ﬂow
seem to be pivotal in the development of type 2 HRS. Prolonged
renal hypoperfusion may result in chronic injury. Importantly,
whether type 2 HRS is purely a functional and potentially revers-
ible disorder or corresponds to underlying chronic renal lesions of
various origin needs to be clariﬁed.
Independent of hypoperfusion and ischemia, patients with
cirrhosis frequently have diseases or comorbidities which may
determine chronic renal injury. The main causes of chronic renal
diseases in patients with cirrhosis are listed in Table 2. The distri-
bution of each of these causes has not been documented yet.
However, about 60% of cirrhotic patients have impaired glucose
tolerance [66]. The incidence of diabetes mellitus may be as high
as 25% in patients with HCV-related cirrhosis [67]. Therefore, it
can be reasonably assumed that diabetic nephropathy is a rela-
tively frequent cause of impaired renal function in cirrhosis. Even
though hypertension is highly uncommon during cirrhosis,
atherosclerosis associated with glomerulosclerosis may also be
relatively frequent. As an example, 20–25% of candidates for
transplantation have signiﬁcant coronary artery disease at evalu-
ation, which illustrates the high incidence of atherosclerotic
changes [68,69].
The identiﬁcation of the cause of renal dysfunction is impor-
tant as the natural history and rate of progression to end-stage
renal disease (ESRD) is variable. For example, diabetic glomerolu-0 vol. 52 j 605–613
Table 3. Proposed diagnostic criteria for hepatorenal syndrome.
2007 criteria [62]
Cirrhosis with ascites
Serum creatinine >133 lmol/L (1.5 mg/dl)
No improvement of serum creatinine (decrease to a level of 6133 lmol/L) after
at least 2 days with diuretic withdrawal and volume expansion with albumin.
The recommended dose of albumin is 1 g/kg of body weight per day up to a
maximum of 100 g/day
Absence of shock
No current or recent treatment with nephrotoxic drugs
Absence of parenchymal kidney disease as indicated by proteinuria >500 mg/
day, microhematuria (>50 red blood cells per high power ﬁeld) and / or
abnormal renal ultrasonography
JOURNAL OF HEPATOLOGYsclerosis in patients with type I diabetes mellitus progresses
more rapidly than IgA nephropathy [70]. However, even if the
cause has been identiﬁed, assessing the prognosis may be a difﬁ-
cult issue. Patients with advanced cirrhosis are more likely to
have several factors contributing to chronic renal changes than
a single cause of renal disease. This assumption is supported by
the frequent ﬁnding of a combination of various glomerular
changes in unselected cirrhotic patients undergoing renal biopsy
during liver transplantation [71,72]. Interestingly, even patients
with apparently preserved renal function may exhibit signiﬁcant
glomerular changes [73].
The usefulness of conventional urinary markers in the identi-
ﬁcation of the cause of kidney injury is limited. As well as in
patients with acute renal failure, the interpretation of urinary
sodium, fractional excretion of sodium and urine osmolality
may be biased by the underlying activation of water and sodium
retention systems, recent or ongoing administration of diuretics
and volume expansion. The usefulness of proteinuria is also lim-
ited, possibly due to low serum protein level. Several reports have
clearly shown that normal quantitative proteinuria does not
exclude glomerular changes [73,74]. In most of the cases, the
objective is to document and quantify renal lesions (i.e., glomer-
ular, vascular and/or tubulo-interstitial) rather than to identify a
speciﬁc cause of renal disease. As far as reliable non invasive
markers are identiﬁed and validated, this end can only be
achieved by renal biopsy.The place of renal biopsy
In patients with acute renal failure, renal biopsy is rarely needed
since, as discussed above, the main causes of acute renal failure
are pre-renal failure and HRS. Characterisation of renal lesions,
if any, is not useful for the management of these conditions. In
contrast, renal biopsy may be useful in patients with chronic
impairment of renal function, before the occurrence of end-stage
renal disease. Pathological examination remains the only way to
document and quantify renal lesions. In theory, percutaneous
kidney biopsy represents the ideal route since, most often, it
allows to obtain adequate tissue samples. However, a substantial
proportion of cirrhotic patients have contraindications to percu-
taneous biopsy due to coagulation disorders. Inspired from trans-
jugular liver biopsy, transjugular renal biopsy has been developed
to overcome these limitations [75–77].
In a large series of non-cirrhotic patients, transjugular route
proved as efﬁcient as percutaneous route, with a comparable rate
of success to obtain adequate samples and a comparable numberJournal of Hepatology 201of glomeruli in each sample (on average 10 for optical microscopy
and 5 for immunoﬂuorescence) [78]. In this study, the rate of
complications was similar with transjugular and percutaneous
routes with major bleeding occurring in about 1%. However, the
rate of complications of percutaneous biopsy seems to be higher
in cirrhotic patients than in non-cirrhotic patients. In one series,
18% of patients had major bleeding complications requiring blood
transfusion [74]. INR above 1.5 was associated with an increased
risk of bleeding. These results suggest that in cirrhotic patients
with mild coagulation changes, transjugular route should be pre-
ferred to percutaneous route. Small size kidneys, poor cortical
differentiation and large volume ascites may preclude this
technique.
Proposed guidelines concerning the indications for renal
biopsy in cirrhotic patients are listed in Table 4.Assessment of cirrhotic patients before liver transplantation
Objectives
The assessment of candidates for transplantation raises speciﬁc
issues. A ﬁrst objective is to assess the mortality risk, given that
pre-transplant renal function predicts post-transplant survival
[79–81]. A pre-transplant GFR less than 40 ml/min was shown
to be associated with signiﬁcantly lower short-term and long-
term survival [81]. A second objective is to identify patients
who are likely to develop end-stage renal disease within the ﬁrst
years following transplantation, while receiving CNI-based
immunosuppression. CNI frequently have nephrotoxic effects by
inducing chronic microangiopathy and interstitial ﬁbrosis
[82,83]. The cumulative incidence of ESRD 10 years after liver
transplantation is of about 20% [84]. In candidates with impaired
renal function, a third objective is to determine whether renal
function will improve with liver transplantation, will be stabi-
lized or will continue to progress. In those who are at risk of
experiencing further deterioration of renal function, the expected
rate of progression should be estimated. Overall, patients with
baseline impairment in renal function should be categorized as
follows: those with reversible renal dysfunction caused by liver
disease and who will recover or have sufﬁcient improvement fol-
lowing transplantation; those who are at risk of delayed ESRD;
and, lastly, those who will not improve following transplantation
or who will rapidly develop ESRD. In the two former groups, com-
bined liver and kidney transplantation (CLKT) is not justiﬁed even
if some of these patients may occasionally need sequential kidney
transplantation several years after liver transplantation. Con-
versely, in the last group, CLKT may be justiﬁed. On the one hand,
patients who already had liver transplantation can be listed for
sequential kidney transplantation at the time they eventually
develop ESRD. On the other hand, if kidney transplantation has
to be performed, CLKT offers several advantages. Firstly, patients
undergo a single procedure. Secondly, waiting time is shorter on
average. CLKT guarantees adequate renal function, without limi-
tations in the use of CNI-based immunosuppression. Lastly, the
liver has immunoprotective effects on the kidney if the donor is
the same [85]. There is no consensus of the minimal interval
between liver transplantation and the expected occurrence of
ESRD which justiﬁes ‘‘pre-emptive” CLKT rather than sequential
kidney transplantation. However, in patients with true GFR
between 30 and 60 ml/min/1.73 m2, an expected interval of 2–0 vol. 52 j 605–613 609
Table 4. Proposed recommendations concerning the indications for renal biopsy in cirrhotic patients.
Acute renal failure
No biopsy if pre-renal failure, HRS type I or acute tubular necrosis, except if
 abnormal duration and no recovery with speciﬁc therapy, or
 candidate for liver transplantation and suspicion of superimposed chronic kidney disease
Biopsy if suspicion of uncommon intrinsic kidney disease (systemic disease, immuno-allergic-induced drug toxicity, thrombotic microangiopathy) with potential
curative intervention
Chronic kidney failure
Biopsy questionable in patients not eligible for liver transplantation. Biopsy not systematically recommended
In patients eligible for liver transplantation: indications depending of GFR*
 GFR < 15 ml/min/1.73 m2 : no indication
 GFR between 15 to 30 ml/min/1.73 m2 : systematic biopsy
 GFR between 30 to 60 ml/min/1.73 m2 : biopsy if suspicion of parenchymal kidney disease as indicated by proteinuria > 500 mg/day, microhematuria (>50 red blood
cells per high power ﬁeld) and / or a recognized cause of chronic kidney disease (diabetes, past history of hypertension, HBV and HCV infection)
 GFR > 60 ml/min/1.73 m2 : no indication
* A decision should be based on measured GFR with exogenous markers, not on estimated GFR.
Review3 years to progress to ESRD seems to be a reasonable limit to con-
sider CLKT.
A decision for CLKT should be based on direct measurement of
GFR using exogenous markers (inulin or iohexol for instance); not
on creatinine or creatinine-based equations. Borderline patients
or patients in whom it remains difﬁcult to distinguish the respec-
tive role of chronic and acute renal changes should undergo
biopsy. Attention should focus on patients with the so called
‘‘HRS” since a substantial proportion of these patients may have
underlying chronic and irreversible kidney injury. The concept
of full recovery of renal function following liver transplantation
in patients with HRS should be revisited. Indeed, several series
have shown that even though, on average, renal function
improves after transplantation, most patients have persistently
high creatinine and/or decreased GFR [70,86–88]. Patients who
had HRS before transplantation develop ESRD more frequently
after transplantation [70,88]. Persistent impairment of renal
function following transplantation could be due to established
renal lesions secondary to ischemia and/or to underlying chronic
lesions of other origin. More data are needed in this population to
identify associated cofactors.
Selection of candidates for combined liver and kidney
transplantation
Since the implementation of MELD score-based allocation sys-
tem, the number of CLKT has dramatically increased, at least in
the United States [89,90]. Indeed, patients with high pre-trans-
plant creatinine have a higher MELD score and, consequently, a
more rapid access to transplantation. The ﬁnding that patients
with serum creatinine >2 mg/dl (176 lmol/L) do better with
CLKT than with liver transplantation alone has been an incentive
to perform combined transplantation [91]. However, in the gen-
eral context of organ shortage, candidates should be carefully
selected in order to guarantee equity and utility.
Generally, pre-transplant dialysis in patients with acute renal
failure (HRS in most cases) is not an indication for kidney trans-
plantation. CLKT should only be considered in patients who have
been on dialysis for more than 8 weeks because, in this situation,
recovery is highly unlikely [88,92]. Otherwise, only patients with
chronic kidney disease should be considered for CLKT. Chronic
kidney disease is deﬁned by either kidney damage or a decrease
in GFR below 60 ml/min/1.73 m2 for 3 months or more [93]. Kid-
ney damage is deﬁned by pathologic abnormalities or markers of
damage including abnormalities in blood or urine tests or imag-610 Journal of Hepatology 201ing studies [93]. CLKT should be considered in patients with GFR
below 30 ml/min and no evidence for an additional factor related
to liver disease which could improve with liver transplantation.
Borderline patients should have a biopsy. It has been proposed
that CLKT should be preferred to liver transplantation alone when
pathology demonstrates more than 30% glomerulosclerosis and/
or more than 30% interstitial ﬁbrosis [92]. CLKT should also be
considered if pathology shows prominent vascular changes since
they might be at higher risk of developing ESRD with calcineurin
inhibitors.Conclusions and perspectives
Physicians involved in the care of patients with cirrhosis have
become even more interested in the assessment of renal function
as, with the advent of MELD score, creatinine was shown to be a
strong prognostic marker. However, in cirrhosis, there is still a
gap between serum creatinine and renal function. Serum creati-
nine and the widely used creatinine-based equations must be
interpreted with caution. In general, true GFR is lower than that
expected on the basis of creatinine-based equations. Until now,
direct measurement using exogenous markers is the only reliable
method to quantify GFR. The reasons why creatinine-based equa-
tions are inaccurate should be clariﬁed with the aim of overcom-
ing inaccuracies. Further studies should be conducted in large
series of cirrhotic patients to correlate true GFR to potential
markers. Only such studies could result in the creation and vali-
dation of more speciﬁc equations for cirrhotic patients. Whether
this goal can be better achieved with creatinine or with other
endogenous markers such as cystatin C needs further investiga-
tions. An improvement in the assessment of baseline renal func-
tion, especially in cirrhotic patients who may have ﬂuctuations in
GFR over time, could result into more accurate prognostic tools.
Even if it is a relatively inaccurate marker of renal function in cir-
rhosis, serum creatinine which has a strong prognostic value can
be used in routine.
Besides the assessment of renal function, other important
issues need to be addressed in the context of cirrhosis. Firstly,
the mechanisms involved in chronic impairment in renal function
during cirrhosis should be clariﬁed. Secondly, the potential
reversibility of impaired renal function is an especially important
issue in candidates for transplantation. Identifying and quantify-
ing renal lesions is mandatory for addressing these issues. There
is no reliable alternative to invasive assessment, including renal0 vol. 52 j 605–613
JOURNAL OF HEPATOLOGY
biopsy. In the future, attempts should be made to correlate non
invasive biomarkers of kidney damage [94–96] to pathological
ﬁndings. The potential contribution of renal artery Doppler ultra-
sonography in the detection of early increase in vascular resis-
tance should be further investigated [50,97]. At present,
accurate assessment of renal function and lesions in cirrhotic
patients is necessarily costly, time consuming and invasive. More
simple and non invasive alternatives are needed.
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